Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced Esophageal Cancer (AIPAAIAEC)

Zhengzhou University

Status: Enrolling

Conditions: Esophageal Neoplasms

Treatments: Drug: an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor

Study type: Observational

Funder types: Other

Identifiers

NCT05349045

2022-KY-0179-002

Details and patient eligibility

About

The combination of an anti-PD-1/PD-L1 antibody with an angiogenesis inhibitor has shown efficacy in many cancers.The purpose of this study is to confirm that the combination of these two drugs can benefit patients with advanced esophageal cancer.

Enrollment: 300 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Esophageal cancer confirmed by histopathology or cytology
2. Unresectable locally advanced/recurrent or metastatic esophageal cancer, or progression after neoadjuvant or adjuvant therapy
3. Esophageal cancer patients who benefit from the use of an anti-PD-1/PD-L1 antibody with an angiogenesis inhibitor evaluated by the researchers
4. Patients who sign informed consent and voluntarily join the study

Exclusion criteria

1. Patients who are recommended not using an anti-PD-1/PD-L1 antibody or an angiogenesis inhibitor in the instructions, or other patients who are judged by the investigators to be unsuitable in the study
2. Patients who are undergoing treatment regimen of blind trial

Trial design

300 participants in 1 patient group

an anti-PD-1/PD-L1 antibody with an angiogenesis inhibitor group

Treatment:

Drug: an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor